➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
McKinsey
Colorcon
Baxter

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DOLOPHINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Dolophine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149630 ↗ Pharmacogenetics of Disulfiram for Cocaine Completed National Institute on Drug Abuse (NIDA) Phase 2 2005-01-01 Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
NCT00149630 ↗ Pharmacogenetics of Disulfiram for Cocaine Completed Yale University Phase 2 2005-01-01 Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
NCT00149630 ↗ Pharmacogenetics of Disulfiram for Cocaine Completed Baylor College of Medicine Phase 2 2005-01-01 Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
NCT00879996 ↗ Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 2009-04-01 The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.
NCT00879996 ↗ Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed National Institute on Drug Abuse (NIDA) Phase 4 2009-04-01 The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.
NCT00879996 ↗ Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed State University of New York at Buffalo Phase 4 2009-04-01 The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dolophine Hydrochloride

Condition Name

Condition Name for Dolophine Hydrochloride
Intervention Trials
Fracture 1
Opioid Dependence 1
Cocaine Dependence 1
Opiate Addiction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dolophine Hydrochloride
Intervention Trials
Pain, Postoperative 3
Behavior, Addictive 1
Kyphosis 1
Cocaine-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dolophine Hydrochloride

Trials by Country

Trials by Country for Dolophine Hydrochloride
Location Trials
United States 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dolophine Hydrochloride
Location Trials
Illinois 2
New York 2
California 1
Maine 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dolophine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dolophine Hydrochloride
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dolophine Hydrochloride
Clinical Trial Phase Trials
Completed 4
Withdrawn 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dolophine Hydrochloride

Sponsor Name

Sponsor Name for Dolophine Hydrochloride
Sponsor Trials
Northwestern University 2
National Institute on Drug Abuse (NIDA) 2
State University of New York at Buffalo 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dolophine Hydrochloride
Sponsor Trials
Other 10
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
Harvard Business School
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.